{
    "clinical_study": {
        "@rank": "16595", 
        "arm_group": {
            "arm_group_label": "Gamma Ventral Capsulotomy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "A research study of the effectiveness and safety of gamma knife ventral capsulotomy in\n      patients with severe intractable obsessive-compulsive disorder (OCD)."
        }, 
        "brief_title": "Safety and Effectiveness of Gamma Capsulotomy in Intractable OCD", 
        "condition": "Obsessive Compulsive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Obsessive-Compulsive Disorder", 
                "Compulsive Personality Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. OCD, diagnosed by Structured Clinical Interview for DSM-IV (SCID-IV), judged of\n             disabling severity with a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of at\n             least 30 and a Social and Occupational Functioning Assessment Scale (SOFAS) score of\n             45 or less.\n\n          2. Persistence of severe symptoms and impairment for five or more years despite: 1. at\n             least three adequate (\u22653 months at the maximum tolerated dose) serotonin transporter\n             inhibitor trials (fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram,\n             escitalopram, or clomipramine) alone or in combination with, 2. adequate behavior\n             therapy (\u226520 sessions of expert exposure and response prevention), and 3.\n             augmentation of one of the selective SRIs with clomipramine, a neuroleptic, and\n             clonazepam.\n\n          3. Age between 18 and 65 years.\n\n          4. Able to understand and comply with instructions.\n\n          5. Able to give fully informed, written consent in the judgment of the Consent Monitor.\n\n          6. Either drug free or on a stable drug regimen for at least 6 weeks.\n\n          7. Good general health.\n\n          8. A family member or significant other, in contact with the patient every 1-3 days, is\n             available and willing to communicate with the research team if the patient's clinical\n             status worsens.\n\n          9. The local referring psychiatrist  is willing to provide ongoing care for the duration\n             of the trial.\n\n        Exclusion Criteria:\n\n          1. Current or past psychotic disorder.\n\n          2. Full-scale IQ below 85 on the Wechsler Abbreviated Scale of Intelligence (WASI),\n\n          3. A clinical history of bipolar mood disorder.\n\n          4. Any current clinically significant neurological disorder or medical illness affecting\n             brain function, other than tic disorders or Tourette syndrome.\n\n          5. Any clinically significant abnormality on preoperative magnetic resonance imaging\n             (MRI).\n\n          6. Inability to undergo presurgical MRI (cardiac pacemaker, pregnancy, metal in body,\n             severe claustrophobia.\n\n          7. Current or unstably remitted substance abuse, dependence, or a positive urine\n             toxicology screen.\n\n          8. Pregnancy and women of childbearing age not using effective contraception.\n\n          9. Unable to adhere to operational and administrative study requirements (in the\n             investigators' judgment).\n\n         10. Clinical history of severe personality disorder.\n\n         11. Imminent risk of suicide (in the investigators' judgment)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01849809", 
            "org_study_id": "IRB#2010-001"
        }, 
        "intervention": {
            "arm_group_label": "Gamma Ventral Capsulotomy", 
            "intervention_name": "Gamma Ventral Capsulotomy", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Providence", 
                    "country": "United States", 
                    "state": "Rhode Island", 
                    "zip": "02906"
                }, 
                "name": "Butler Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Effectiveness of Gamma Capsulotomy in Intractable Obsessive Compulsive Disorder", 
        "overall_official": {
            "affiliation": "Butler Hospital", 
            "last_name": "Steven Rasmussen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Yale-Brown Obsessive Compulsive Severity Scale", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline to 1 month, 6 months, 1 year, and then every year up to 30 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01849809"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Butler Hospital", 
            "investigator_full_name": "Steven Rasmussen", 
            "investigator_title": "Medical Director, Butler Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Butler Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Butler Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 1993", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}